Powered by
GRAND RAPIDS—Officials at Tetra Therapeutics, a pharma startup developing drugs to treat brain disorders associated with cognitive and memory deficits, announced that CEO Mark Gurney had retired effective June 30. …
ANN ARBOR—Officials at the Ann Arbor cholesterol drug developer Esperion Therapeutics Inc. (Nasdaq: ESPR) announced the appointment of JoAnne Micale Foody, MD, FACC, FAHA as chief medical officer, effective immediately. …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) announced the appointment of Sheldon Koenig as president, CEO, and board member, effective immediately. He succeeds Tim Mayleben, whom company officials said “decided to …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) reported a loss of $90.8 million or $3.50 a share in the first quarter ended March 31, vs. a loss of $78.2 million or …
ANN ARBOR—Esperion Therapeutics (NASDAQ: ESPR), developers of a novel class of cholesterol-reducing drugs, announced that an investor group led by New York City-based Oberland Capital Management LLC agreed to provide …
Esperion expands partnership with Daiichi Sankyo Group ANN ARBOR–Esperion Therapeutics (NASDAQ: ESPR), developers of a new class of cholesterol-lowering drugs, announced it has entered into a licensing agreement with Daiichi …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor-based developer of cholesterol-lowering drugs, announced that the results of a Phase 2 study evaluating the combination of its Nexletol (bempedoic acid) …
ANN ARBOR—Esperion Therapeutics Inc. reported a 150 percent increase in sales for its new cholesterol-lowering drug between the third quarter and the fourth quarter ended Dec. 31. Overall, the company …
CANTON TWP.–MMS Holdings, a contract research organization for the pharmaceutical industry, has joined the Decentralized Trials and Research Alliance, an organization launched in December to unite healthcare companies, regulators, patient …
ANN ARBOR—Esperion Therapeutics Inc., the Ann Arbor developer of novel cholesterol-fighting drugs, announced preliminary financial results and a new licensing agreement with Pittsford, N.Y.-based drug developer Serometrix. “As a result …